ScreenerHero

CLRB Cellectar Biosciences, Inc.

NAS · US · Healthcare · Biotechnology · cellectar.com
1.510USD0.00%Mkt Cap: 14.27M $P/E: —

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid d…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap14.27M USD
Enterprise Value-18.19M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-21.79M USD
Revenue/Share—
Last Price1.510 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees11
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.79
PEG—
EV/EBITDA0.78
EV/Revenue—
P/S—
P/B0.42
EPS (TTM)-3.17
EPS (Forward)-1.92
52W Range
1.4601% of range6.520
52W High6.520 USD
52W Low1.460 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-255.25%
ROA-145.48%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-23.12M USD
CapEx (TTM)5.88K USD
FCF Margin—
FCF Yield-87.72%
Net Debt-32.46M USD
Net Debt/EBITDA1.39
Balance Sheet
Debt/Equity0.05
Current Ratio6.66
Quick Ratio6.49
Book Value/Sh3.62 USD
Cash/Share3.60 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateJul 17, 2018
Splits
Last Split1:30
Split DateJun 24, 2025
Analyst Consensus
Rating—
Target (Mean)11.50 USD
Upside (mean)+661.6%
Target Range10.00 USD – 15.00 USD
10.00+661.6% to mean15.00
# Analysts4
Ownership
Shares Out.9.45M
Float9.28M
Insiders1.75%
Institutions34.71%
Short Interest
Short Ratio5.5d
Short % Float2.03%
Short % Out.2.02%
Shares Short191.13K
Short (prev mo.)161.20K
Technical
SMA 502.353 (-35.8%)
SMA 2002.798 (-46.0%)
Beta0.58
S&P 52W Chg16.45%
Avg Vol (30d)59.96K
Avg Vol (10d)82.84K
Technical Indicators
RSI (14)17.2
MACD-0.2278
MACD Signal-0.1776
MACD Hist.-0.0502
BB Upper2.664 USD
BB Middle2.043 USD
BB Lower1.423 USD
BB Width60.75%
ATR (14)0.1426 USD
Vol Ratio (20d)0.61x